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Abstract
Background Impaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Tica-
grelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in 
those with versus without IRF.
Methods A pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental 
strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 
12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and stable coronary 
artery disease (CAD) patients stratified according to IRF (glomerular filtration rate < 60 ml/min/1.73 m2).
Results At 2 years, patients with IRF (n = 2171) had a higher rate of the primary endpoint (all-cause mortality or centrally 
adjudicated, new Q-wave myocardial infarction [MI](hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.35–1.98, 
padj = 0.001), all-cause death, site-reported MI, all revascularization and BARC 3 or 5 type bleeding, compared with patients 
without IRF. Among patients with IRF, there were similar rates of the primary endpoint (HR 0.82, 95% CI 0.61–1.11, 
p = 0.192, pint = 0.680) and BARC 3 or 5 type bleeding (HR 1.10, 95% CI 0.71–1.71, p = 0.656, pint = 0.506) in the experi-
mental versus the reference group. No significant interactions were seen between IRF and treatment effect for any of the 
secondary outcome variables. Among ACS patients with IRF, there were no between-group differences in the rates of the 
primary endpoint or BARC 3 or 5 type bleeding; however, the rates of the patient-oriented composite endpoint (POCE) of 
all-cause death, any stroke, MI, or revascularization (pint = 0.028) and net adverse clinical events (POCE and BARC 3 or 5 
type bleeding) (pint = 0.045), were lower in the experimental versus the reference group. No treatment effects were found in 
stable CAD patients categorized according to presence of IRF.
Conclusions IRF negatively impacted long-term prognosis after PCI. There were no differential treatment effects found with 
regard to all-cause death or new Q-wave MI after PCI in patients with IRF treated with ticagrelor monotherapy.
Clinical trial registration The trial has been registered with ClinicalTrials.gov, number NCT01813435.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0039 2-019-01586 -9) contains 
supplementary material, which is available to authorized users.
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Background
Impaired renal function (IRF) is an independent predictor 
of ischemic and bleeding events [1–6]. Despite registries 
suggesting a progressive increase in the number of patients 
with IRF, these patients still tend to be under represented 
or excluded from clinical trials, and undertreated in real 
life [1, 2]. Antiplatelet treatment in patients with IRF is, 
therefore, complex because IRF can effect thrombocyte 
function and coagulation [7], and this is further compli-
cated by the change in drug pharmacokinetics in chronic 
kidney disease [2, 7, 8]. In the PLATO study, the com-
bination of ticagrelor with aspirin substantially reduced 
cardiovascular death, myocardial infarction (MI), or stroke 
compared with clopidogrel plus aspirin in patients with 
acute coronary syndrome (ACS), with a consistent rela-
tive risk reduction in patients with and without IRF and a 
greater absolute risk reduction for patients with IRF [9]. 
This benefit was not associated with a significant increase 
in major bleeding; however, numerically more non–pro-
cedure–related bleeding events were observed among 
patients with IRF [9].
In an attempt to mitigate bleeding risk whilst preserving 
ischemic efficacy, aspirin-free antiplatelet regimens utiliz-
ing more potent  P2Y12 antagonists have been advocated 
[10]. The first and largest trial to date evaluating this con-
cept—GLOBAL LEADERS—failed to show superiority 
of ticagrelor monotherapy starting one month post percu-
taneous coronary intervention (PCI), compared to stand-
ard dual antiplatelet therapy (DAPT) followed by aspirin 
monotherapy in an all comer patient population [11]. Nev-
ertheless, understanding the impact of IRF on long-term 
outcomes after PCI in this large all-comer contemporary 
trial is of clinical interest.
Given this background, we report the results of this pre-
specified analysis according to an estimated glomerular 
filtration rate (eGFR) of 60 ml/min/1.73 m2 and the five 
major categories of renal impairment, defined by the Kidney 
Disease: Improving Global Outcomes (KDIGO) classifica-
tion [12]. In addition, as the randomization in this trial was 
stratified according to clinical presentation (ACS vs. stable 
coronary artery disease [CAD]), we assessed the experimen-
tal treatment effects in relation to baseline renal function 
specifically in ACS and stable CAD patients.
Methods and patients
This is a pre-specified subgroup analysis of the GLOBAL 
LEADERS trial (NCT01813435). GLOBAL LEADERS was 
an investigator-initiated, randomized, multi-center, open-
label trial designed to evaluate two strategies of antiplatelet 
therapy after PCI using uniformly bivalirudin and biolimus 
A9-eluting stents (Biomatrix) in an all-comers population 
[13, 14]. In the experimental treatment strategy, patients 
received aspirin 75–100 mg once daily in combination with 
ticagrelor 90 mg twice daily for one month; followed by tica-
grelor 90 mg twice daily alone for 23 months (irrespective of 
the clinical presentation). In the reference treatment strategy, 
patients received aspirin 75–100 mg daily in combination 
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with either clopidogrel 75 mg once daily in patients with 
stable CAD or ticagrelor 90 mg twice daily in patients with 
ACS for 1 year; followed by aspirin 75–100 mg once daily 
alone for the following 12 months (from 12 to 24 months 
after PCI).
The trial was approved by the institutional review board at 
each participating institution. All patients provided informed 
consent. The study complied with the Declaration of Hel-
sinki and Good Clinical Practices. An independent data 
and safety monitoring committee oversaw the safety of all 
patients.
In the present analyses, patients were stratified according 
to an eGFR cut-off of 60 ml/min/1.73 m2, calculated accord-
ing to the MDRD equation [15], as pre-specified in the trial 
protocol. In addition, exploratory analyses were performed 
stratifying the overall population, and specifically the ACS 
and stable CAD subgroups, according to the KDIGO clas-
sification with chronic kidney disease stage I, II, III, IV, and 
V defined as respective eGFRs of ≥ 90, 60–89, 44–59,15–29 
and < 15 ml/min/1.73 m2 [12].
Patients were followed up at 30 days and 3, 6, 12, 18, 
and 24 months after the index procedure. Electrocardio-
gram (ECG) was obtained at discharge, 3-month and 2-year 
follow-up and during the follow-up if there was suspected 
ischemic event or repeat revascularization. All ECGs were 
analyzed at the core laboratory (Cardialysis, Rotterdam, 
Netherlands) by technicians who were blinded to the treat-
ment assignments.
Study endpoints
The primary endpoint of the present study was the com-
posite of all-cause mortality and new Q-wave myocardial 
infarction (MI) within 2 years after the index procedure. 
The survival status of the patients lost to follow-up or those 
who withdrew their consent was obtained via public civil 
registries in all but eight patients; complete vital status at 
2 years was available in 99.95% [11]. Minnesota classifi-
cation was used to define the new Q-wave MI which was 
centrally adjudicated by an independent ECG core lab [16]. 
The key secondary safety endpoint was investigator-reported 
bleeding academic research consortium (BARC) type 3 or 5 
[17]. Further secondary endpoints included the following: 
individual components of the primary endpoint (all-cause 
death, new Q-wave MI), individual components of key sec-
ondary safety endpoint (BARC defined bleeding type 3 and 
type 5) any stroke, site-reported MI, any revascularization, 
target vessel revascularization (TVR), definite stent throm-
bosis (ST) and the composite of the definite or probable ST, 
defined according to the Academic Research Consortium 
criteria [18].
Finally, the patient-oriented composite endpoint 
(POCE)—advocated by academic research consortium 
(ARC)-2, and net adverse clinical events (NACE) were ana-
lyzed up to 2 years [17, 19, 20]. The POCE was defined as 
the composite of all-cause death, any stroke, site-reported 
MI (including periprocedural or spontaneous with ST 
elevation MI [STEMI] or non-ST-segment elevation MI 
[NSTEMI]) and any revascularization (re-PCI or coronary 
artery bypass graft surgery [CABG] in the target or non-
target vessel) [19], whereas NACE combined POCE and 
BARC 3 or 5 type bleeding [21, 22].
The trial was monitored for event under-reporting and 
event definition consistency. There were seven on-site 
monitoring visits performed at individual sites, with 20% of 
reported events checked against source documents. There 
was no independent adjudication of clinical events [11, 13].
Statistical analysis
All the analyses were performed on the intention-to-
treat population. Continuous variables are expressed as 
mean ± standard deviation and were compared using inde-
pendent t test. Categorical variables are presented as counts 
and percentage and were compared using Chi square test. 
Kaplan–Meier method was used to estimate the cumulative 
rates of events and Log-rank test was performed to examine 
the differences between groups. The effect of IRF on the 
outcomes was assessed in the univariable and multivariable 
Cox proportional hazards model. The covariates in the mul-
tivariable model included age, gender, diabetes, presenta-
tion of ACS, diabetes mellitus, hypertension, hypercholes-
terolemia, history of stroke, MI, PCI, peripheral vascular 
disease, COPD and previous major bleeding and current 
smoking. Hazard ratios (HRs) and 95% confidence intervals 
(CIs) were calculated from the model and interaction test 
was performed to evaluate the differences in the treatment 
effect of antiplatelet strategy in IRF and non-IRF patients. A 
schematic summary of the performed analyses in the overall 
cohort and specifically among stable CAD and ACS patients 
is presented in Table 1. No procedures were prespecified 
for multiple testing for subgroup analyses of the trial and, 
therefore, all presented findings should be considered as 
exploratory. Analyses were performed in SPSS 25. A two-
sided p value less than 0.05 was considered as statistical 
significance.
Results
Study population
The GLOBAL LEADERS trial recruited and randomly 
assigned 15,991 participants; as 23 patients subsequently 
withdrew consent and requested deletion of their data from 
the database, a total of 15,968 patients remained in the study 
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[11]; of these, 15,883 patients (99.5%) had a baseline serum 
creatinine level available.
There were 2171 patients with IRF identified using 
MDRD-derived eGFR threshold of 60 ml/min/1.73 m2 in 
this study (Suppl. Figure 1). Patients with IRF were older, 
were more often female, diabetic, hypertensive or hyper-
cholesterolemic, more often had a history of prior stroke, 
prior PCI or CABG, prior MI, COPD, or peripheral vas-
cular disease or a history of previous major bleeding and 
were less frequently smoking. Patients with IRF presented 
more often with stable CAD (Table 2). Patients with IRF had 
more often left main coronary artery treated and had a larger 
number of stents implanted. Direct stenting and aspiration 
thrombectomy were performed less often in patients with 
IRF, compared with patients without IRF (Table 3).
The baseline clinical characteristics were balanced 
between the experimental and the reference arm for both 
IRF and non-IRF subgroups, except for a higher proportion 
of hypertensive patients in the IRF subgroup receiving the 
experimental strategy, and lower proportion of patients with 
peripheral vascular disease among non-IRF patients in the 
experimental arm (Suppl. Table 1).
Patients with IRF had a consistently lower treatment 
adherence at each follow-up visit (Suppl. Table 2). At 1 year, 
among IRF patients 769 out of 1013 (75.9%) versus 828 
out of 969 (85.4%) adhered to the experimental and refer-
ence strategy, respectively. Among non-IRF patients, these 
proportions were 5372 out of 6684 (82.7%) versus 5863 
out of 6527 (89.8%), respectively. At 2 years, 718 out of 
999 (71.9%) versus 859 out of 949 (90.5%) patients with 
IRF, and 5062 out of 6445 (78.5%) versus 6092 out of 6513 
(93.5%) non-IRF patients adhered to the experimental and 
reference strategies, respectively (Suppl. Table 3).
Table 1  Schematic summary of clinical outcome analyses performed in the overall cohort and in the subgroups according to clinical presentation
eGFR estimated glomerular filtration rate
Overall population
Analyses according to prespecified eGFR cut-off of 60 ml/min
Figure 1, Tables 4 and 5, Suppl. Table 4
Analyses according to KDIGO-defined eGRF subgroups (5 major categories)
Suppl. Figure 2
Analyses with eGFR treated as a continuous variable
Fig. 2
Stable coronary artery disease Acute coronary syndrome
Analyses according to prespecified eGFR cut-off of 60 ml/min
Fig. 3
Analyses according to prespecified eGFR cut-off of 60 ml/min
Fig. 3
Analyses according to KDIGO-defined eGRF subgroups (5 major categories) 
Suppl. Table 5
Analyses according to KDIGO-defined eGRF subgroups (5 
major categories) Suppl. Table 5
Table 2  Baseline clinical characteristics
IRF—impaired renal function, CABG—coronary artery bypass graft-
ing, CAD—coronary artery disease, COPD—chronic obstructive pul-
monary disease, MI—myocardial infarction, NSTEMI—non-ST seg-
ment elevation myocardial infarction, PCI—percutaneous coronary 
intervention, SD—standard deviation, STEMI—ST-segment elevation 
myocardial infarction, UA—unstable angina
Non-IRF (n = n = 13,712) IRF 
(n = 2171)
p value
N (%) N (%)
Age > 75 years 1726 12.6 827 38.1 0.001
Sex (female) 2873 21.0 823 37.9 0.001
Acute coronary 
syndrome
6495 47.4 967 44.5 0.014
 UA 1730 26.6 288 29.8 0.005
 NSTEMI 2908 44.8 449 46.4
 STEMI 1857 28.6 230 23.8
Diabetes mellitus 3189 23.3 838 38.6 0.001
Insulin-treated dia-
betes mellitus
869 6.4 352 16.2 0.001
Hypertension 9774 71.5 1889 87.1 0.001
Hypercholester-
olemia
9197 69.2 1513 72.1 0.008
Previous stroke 
more than 
30 days ago
329 2.4 92 4.2 0.001
Previous MI 3081 22.5 613 28.3 0.001
Previous PCI 4358 31.8 843 38.8 0.001
Previous CABG 743 5.4 198 9.1 0.001
Peripheral vascular 
disease
753 5.5 247 11.5 0.001
COPD 664 4.9 155 7.2 0.001
Previous major 
bleeding or 
predisposition to 
bleeding
77 0.6 21 1.0 0.025
Current smoker 3825 27.9 318 14.6 0.001
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Clinical outcomes in relation to renal function
Patients with IRF had a significantly higher rate of 
the primary endpoint (HR 1.64, 95% CI 1.35–1.98, p 
adjusted = 0.001), all-cause death (HR 1.82, 95% CI 
1.46–2.26, p adjusted = 0.001), MI (HR 1.55, 95% CI 
1.22–1.96, p adjusted = 0.001), all revascularization (HR 
1.19, 95% CI 1.02–1.37, p adjusted = 0.023), TVR (HR 1.22, 
95% CI 1.01–1.49, p adjusted = 0.044), BARC type 3 bleed-
ing (HR 1.45, 95% CI 1.09–1.92, p adjusted = 0.012), BARC 
type 3 or 5 bleeding (HR 1.40, 95% CI 1.07–1.85, p = 0.016), 
and BARC type 2,3,5 bleeding (HR 1.22, 95% CI 1.03–1.44, 
p adjusted = 0.019) (Table 4).
Clinical outcomes in relation to renal function 
and randomized treatment strategy
At 2 years, among patients with IRF, the primary endpoint 
occurred in 79 patients (7.2%) in the experimental arm and 
in 93 patients (8.7%) in the reference group (HR 0.82, 95% 
CI 0.61–1.11, p = 0.192, pint = 0.680). Among patients with 
IRF there were no significant between-group differences in 
the rates of all-cause death (HR 0.76; 95% CI 0.55–1.06; 
p = 0.105), POCE (HR 0.86, 95% CI 0.71–1.04, p = 0.128), 
NACE (HR 0.89, 95% CI 0.74–1.07, p = 0.228) and BARC 
type 3 or 5 type (HR 1.10, 95% CI 0.71–1.71, p = 0.656) 
(Table 5). No significant interactions were found between 
IRF and treatment effect for any of the outcome variables 
at 1- and 2-year follow-up (Fig. 1, Suppl. Figure 2, Suppl. 
Table 4). However, when treating eGFR as a continuous 
variable, there was a differential treatment effect with 
Table 3  Angiographic and 
procedural characteristics in 
patients categorized according 
to baseline function using a 
prespecified eGFR cut-off of 
60 ml/min (n = 15,883)
Data shown are n (%), unless otherwise indicated
SD standard deviation
‡ Calculated per lesion and analyzed with general or generalized linear mixed-effects models with a random 
effect for patients to account for multiple lesions treated within patient
Non-IRF (n = 13,712) IRF (n = 2171) p value
Patient level
 Index PCI attempted 13,639 2160 0.878
 Lesion treated at index PCI 0.474
  One lesion 10,148 (74.7) 1588 (73.7)
  Two lesions 2719 (20.0) 456 (21.2)
  Three or more lesions 712 (5.2) 111 (5.2)
Lesion  level‡
 Number of lesion treated 17,884 2854
 Vessel treated 0.001
  Left main coronary artery 308 (1.7) 78 (2.7)
  Left anterior descending artery 7510 (42.0) 1115 (39.1)
  Left circumflex artery 4350 (24.3) 703 (24.6)
  Right coronary artery 5548 (31.0) 906 (31.7)
  Bypass graft 168 (0.9) 52 (1.8)
 Number of stent per lesion, mean ± SD 1.19 ± 0.53 1.22 ± 0.58 0.019
 Mean stent length, mean ± SD 24.76 ± 13.79 25.15 ± 15.07 0.193
 Mean stent diameter, mean ± SD 2.99 ± 0.47 2.97 ± 0.46 0.101
 Direct stenting 5826 (33.1) 819 (29.2) 0.001
 Bifurcation PCI 2176 (12.2) 330 (11.6) 0.357
 Aspiration thrombectomy 936 (5.2) 95 (3.3) 0.001
 TIMI pre 0.001
  0 or 1 2315 (13.7) 290 (10.6)
  2 1983 (11.7) 367 (13.5)
  3 12,616 (74.6) 2068 (75.9)
 TIMI post 0.771
  0 or 1 65 (0.4) 8 (0.3)
  2 83 (0.5) 13 (0.5)
  3 17,187 (99.1) 2765 (99.2)
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regard to rates of BARC 3 type (pint = 0.019) and BARC 
3 or 5 type bleeding (pint = 0.006), being less frequently 
observed in the experimental than in the reference arm by 
decreasing eGFR (Fig. 2).
Clinical outcomes in relation to extent of renal 
dysfunction and randomized treatment strategy
The experimental treatment strategy was associated with 
a lower rates of the primary endpoint, all-cause mortal-
ity, any revascularizations, TVR, POCE and NACE ver-
sus the reference treatment, with progressively decreasing 
point estimates of the HR with decreasing cut-off values 
of eGFR from 90 to 15 ml/min; however, no significant 
interactions were found between KDIGO defined eGFR 
categories and treatment effect for any of the outcome 
variables (Suppl. Figure 2).
Clinical outcomes in ACS and stable CAD patients 
with impaired renal function
Among ACS patients, individuals with impaired renal 
function had similar rates of the primary endpoint (HR 
0.71; 95% CI 0.47–1.06; p = 0.094, pint = 0.305) and 
BARC 3 or 5 type bleeding (HR 0.68; 95% CI 0.36–1.27; 
p = 0.227; pint = 0.841) in both treatment groups, but 
there was a lower rate of POCE (HR 0.71, 95% CI 
0.53–0.93, p = 0.014, pint = 0.028) and NACE (0.71, 95% 
CI 0.54–0.92, p = 0.010, pint = 0.045) in the experimental 
arm (Fig. 3). No treatment effects were seen in stable CAD 
patients categorized according to presence of IRF (Fig. 3). 
The results of KDIGO-stratified analysis of clinical out-
comes in the experimental versus the reference group in 
the overall population and specifically for stable CAD 
and ACS patients are presented in the Suppl. Figure 2 and 
Suppl. Table 5.
Table 4  Two year clinical outcomes in relation to baseline renal function impairment using a prespecified cut-off of 60 ml/min according to the 
MDRD equation (n = 15,883)
Hazard ratio (HR) adjusted, when appropriate, for age, sex, clinical presentation with ACS, diabetes mellitus, hypertension, hypercholester-
olemia, previous myocardial infarction, percutaneous coronary intervention or stroke, history of previous major bleeding, peripheral vascular 
disease, chronic obstructive pulmonary disease, current smoking, and randomized treatment. The primary endpoint was a composite of 2-year 
all-cause mortality or nonfatal, centrally adjudicated, new Q-wave myocardial infarction (MI). Patient-oriented composite endpoint (POCE) 
included all-cause mortality or any MI, revascularization or stroke, whereas net adverse clinical events (NACE) comprised POCE, bleeding aca-
demic research consortium (BARC)-defined bleeding type 3 or 5 type
HR—hazard ratio, 95% CI—95% confidence interval, ST—stent thrombosis, MDRD—modification of diet in renal disease
*Not including transient ischemic attack
Non-IRF 
(n = 13,712)
IRF (n = 2171) Unadjusted HR 95% CI p value Adjusted HR 95% CI p value
N (%) N (%)
Primary endpoint 479 3.5 172 7.9 2.32 (1.95–2.76) 0.001 1.64 (1.35–1.98) 0.001
 All-cause death 334 2.4 141 6.5 2.73 (2.24–3.32) 0.001 1.82 (1.46–2.26) 0.001
 New Q-wave MI 154 1.1 32 1.5 1.34 (0.92–1.96) 0.130 1.05 (0.70–1.59) 0.801
BARC 3 or 5 250 1.8 81 3.7 2.10 (1.64–2.70) 0.001 1.40 (1.07–1.85) 0.016
 BARC 3 232 1.7 76 3.5 2.13 (1.64–2.76) 0.001 1.45 (1.09–1.92) 0.012
 BARC 5 33 0.2 13 0.6 2.54 (1.34–4.82) 0.004 1.41 (0.70–2.84) 0.337
Stroke* 125 0.9 37 1.7 1.92 (1.33–2.77) 0.001 1.18 (0.79–1.76) 0.410
MI (site reported) 392 2.9 105 4.8 1.74 (1.40–2.16) 0.001 1.55 (1.22–1.96) 0.001
Revascularization 1278 9.3 242 11.1 1.24 (1.08–1.42) 0.003 1.19 (1.02–1.37) 0.023
 Target vessel revascularization 686 5.0 138 6.4 1.31 (1.09–1.57) 0.004 1.22 (1.01–1.49) 0.044
Definite ST 109 0.8 19 0.9 1.12 (0.69–1.82) 0.652 1.25 (0.73–2.11) 0.415
Definite/probable ST 134 1.0 30 1.4 1.44 (0.97–2.13) 0.074 1.50 (0.97–2.31) 0.069
POCE 1755 12.8 413 19.0 1.55 (1.39–1.72) 0.001 1.33 (1.19–1.50) 0.001
NACE 1910 13.9 458 21.1 1.59 (1.43–1.76) 0.001 1.34 (1.20–1.49) 0.001
Additional bleeding endpoints
 BARC 2 644 4.7 136 6.3 1.37 (1.14–1.64) 0.001 1.15 (0.94–1.40) 0.181
 BARC 2, 3 or 5 853 6.2 202 9.3 1.54 (1.32–1.80) 0.001 1.22 (1.03–1.44) 0.019
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Discussion
The main findings of this prespecified sub-analysis of the 
GLOBAL LEADERS trial can be summarized as follows:
(1) The incidence of IRF in this large, contemporary, unse-
lected patient population undergoing PCI, was 13.7% 
(13% in patients undergoing PCI for ACS and 14.3% 
in patients undergoing PCI for stable CAD).
(2) Among patients undergoing PCI, any degree of IRF is 
associated with a higher risk of mortality, ischemic and 
bleeding events.
(3) In the overall population, there was no differential treat-
ment effect on safety or efficacy with long-term ticagre-
lor monotherapy after 1-month DAPT among patients 
with and without IRF. Nevertheless, post hoc explora-
tory analyses including eGFR as a continuous variable 
showed a differential treatment effect on BARC 3 or 5 
type bleeding, with less BARC 3 or 5 type bleeding in 
the experimental group.
This study is currently the largest baseline eGFR-stratified 
analysis of ischemic and bleeding outcomes in PCI patients 
receiving monotherapy with a potent  P2Y12 antagonist, fol-
lowing 1 month DAPT.
Fig. 1  Two-year clinical outcomes in patients stratified according to 
presence of impaired renal function* and randomized treatment. The 
primary endpoint was a composite of 2-year all-cause mortality or 
nonfatal, centrally adjudicated, new Q-wave myocardial infarction 
(MI). Patient-oriented clinical outcome (POCE) included all-cause 
mortality or any MI, revascularization or stroke, whereas net adverse 
clinical events (NACE) comprised POCE, BARC 3 or 5 type bleed-
ing. ST—stent thrombosis. * based on modification of diet in renal 
disease (MDRD) equation, using a prespecified cut-off of 60 ml/min
Fig. 2  Interaction of treatment safety (BARC 3 or 5 type bleeding) 
with baseline eGFR (the experimental vs. the reference treatment 
group). The line represents the hazard ratios, the colored areas rep-
resent the 95% confidence intervals. The p value denotes the interac-
tion term between the randomized treatment effects on BARC 3 or 5 
type bleeding and the estimated glomerular filtration rate, treated as a 
continuous variable. Cox proportional hazard model was used. Blue 
line/area—the experimental treatment, Red line/area—the reference 
treatment
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Based on the PLATO study, which demonstrated tica-
grelor’s superiority over clopidogrel in patients with ACS 
regardless of baseline renal function, and its increasing 
advantage in reducing major adverse cardiac events in 
cohorts with worsening renal dysfunction, it was of interest 
to evaluate whether similar findings could be replicated with 
ticagrelor monotherapy after 1 month of DAPT in an unse-
lected patient population undergoing PCI. Indeed, compared 
to the reference treatment, the experimental treatment group 
had non-significantly lower rates of the primary endpoint 
and all-cause mortality, with progressively decreasing point 
estimates of the HR with decreasing cutoff values of eGFR 
from 90 to 30 ml/min. However, no significant interaction 
term was detected between the randomized treatment and 
IRF for any of the outcomes. The safety profile of ticagrelor 
in this large contemporary PCI cohort may facilitate better 
informed clinical decisions on the use of the more potent 
 P2Y12 antagonists in patients with IRF undergoing PCI. Fur-
ther research may also establish whether the experimental 
treatment strategy represents a good alternative in selected 
patients with IRF, such as those in whom standard DAPT 
is contra-indicated due to expected excess bleeding risk. 
Of note, IRF is considered as a major or minor bleeding 
risk criterion based on the degree of renal dysfunction, as 
described in the recent consensus document from the Aca-
demic Research Consortium for High Bleeding Risk [23].
However, neither the analysis stratifying patients 
according to baseline IRF status nor the KDIGO catego-
ries were powered to detect between-group differences or 
treatment-by-subgroup interactions. Thus, the present analy-
sis should be considered strictly exploratory, and interpreted 
in the context of the neutral primary analysis of the parent 
trial [11] and the limitations inherent to subgroup analyses 
[24].
Reported clinical outcomes, in particular bleeding rates, 
should also be interpreted in light of the lower adherence 
to the randomized treatment in the experimental arm, in 
particular among patients with IRF who had a consistently 
lower attendance at each follow-up visit. Importantly, how-
ever, discontinuation rates in GLOBAL LEADERS were 
comparable to other trials evaluating ticagrelor [25, 26].
Reassuringly, there was no excess in bleeding risk related 
to the experimental therapy among patients with moderate 
IRF (eGFR = 30–59 ml/min/1.73 m2: n = 2055); however, 
in patients with an eGFR of < 30 ml/min/1.73 m2 (n = 116) 
BARC 3 or 5 type bleeding occurred in 4 out of 61 patients 
in the experimental arm and in 1 out of 55 patients in the 
reference arm; all but one event occurred in patients present-
ing with stable CAD.
This corresponds with previous pharmacodynamic stud-
ies showing that exposure to ticagrelor was approximately 
20% lower, and exposure to the active metabolite approxi-
mately 17% higher, in patients with severe renal impairment 
(eGFR < 30 ml/min/1.73 m2) compared to subjects with nor-
mal renal function.
Exploratory analyses suggested that the potential net 
clinical benefit of the experimental strategy in ACS patients 
with IRF was mainly observed in patients with grade 3 renal 
Fig. 3  Impact of the randomized treatment on 2-year clinical out-
comes according to prespecified eGFR cut off of 60 ml/min (accord-
ing to MDRD equation) in stable CAD and ACS patients. The pri-
mary endpoint was a composite of 2-year all-cause mortality or 
nonfatal, centrally adjudicated, new Q-wave myocardial infarction 
(MI). Patient oriented clinical outcome (POCE) included all-cause 
mortality or any MI, revascularization or stroke, whereas net adverse 
clinical events (NACE) comprised POCE, BARC 3 or 5 type bleed-
ing. ST—stent thrombosis, MDRD—modification of diet in renal dis-
ease
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impairment (eGFR = 30–59 ml/min/1.73 m2). A plausible 
explanation is that the selection of chronic kidney disease 
patients is an effective way to identify high-risk patients 
with high event rates, and the subgroup with moderate renal 
impairment has the greatest reduction in ischemic events, 
without a corresponding increased bleeding risk [2, 7]. This 
further underscores the prominent role of IRF as a compo-
nent of ischemia and bleeding prediction scores used for 
antiplatelet therapy planning [4, 11, 27].
The present results obtained in the ACS population 
are very consistent with the PLATO data in showing the 
excess risk in IRF patients [(19.0% IRF vs. 12.8% no 
IRF, for POCE in GLOBAL LEADERS) vs. (19.7% vs. 
8.4% for death/MI/stroke in PLATO)] with incremental 
risk with more severe renal dysfunction. In the two stud-
ies also, there was a greater absolute all-cause mortality 
risk reduction found among IRF patients, as compared to 
that of patients with normal renal function [9]. In both 
studies also, the bleeding excess with ticagrelor appears 
to be of similar magnitude in IRF and no IRF patients. 
This leads to a favorable net clinical benefit with ticagre-
lor in the two sub-studies. The combined effect of IRF 
and ACS on ischemic outcomes appears to benefit from 
ticagrelor use, probably related to the inadequate platelet 
inhibition achieved with earlier generation  P2Y12 inhibi-
tors (e.g., clopidogrel) in patients having both conditions 
[3, 8]. Whether this is ticagrelor-specific is uncertain as 
close findings have been reported with prasugrel [28] 
and in a metaanalysis [29]. In addition, recently among 
patients who presented with ACS with or without ST-
segment elevation enrolled in the randomized open-label 
ISAR REACT 5 trial, the incidence of death, myocardial 
infarction, or stroke was significantly lower in the group 
receiving prasugrel, compared with the group treated with 
ticagrelor, and the incidence of major bleeding (bleed-
ing BARC 3, 4 or 5 type) was not significantly different 
between the two groups [30]. Nevertheless, among the 
elderly ≥ 70  years of age being treated for a non-ST-
segment elevation ACS the results of POPular AGE trial 
showed that clopidogrel was associated with less bleed-
ing and similar ischemic events versus more potent  P2Y12 
inhibitors (ticagrelor or prasugrel) [31].
The poorer long-term prognosis of patients with IRF 
is possibly explained by more prevalent pre-existing 
cardiovascular disease, more extensive atherosclerosis, 
more frequent high-risk presentations of ACS, lower 
rates of complete revascularization, and underutiliza-
tion of guideline-recommended therapies [2, 32]. Renal 
disease can alter thrombocyte function, coagulation and 
cause endothelial dysfunction [7, 33, 34]. In this context, 
it is noteworthy that among patients with ACS, ticagrelor 
monotherapy, after 1-month DAPT, reduced the rates of 
POCE and NACE among patients with IRF, without an 
increase in BARC 3 or 5 type bleeding, compared to stand-
ard 12-month DAPT after PCI.
In the present analysis, stable CAD patients with IRF 
had a similar rate of ischemic events, and a non-signif-
icantly higher relative risk of BARC 3 or 5 type bleed-
ing in the experimental versus the reference group. In the 
PEGASUS-TIMI 54 trial, ticagrelor was associated with an 
increase in Thrombolysis in Myocardial Infarction (TIMI) 
major bleeding in stable outpatients with prior  MI12. Nev-
ertheless, as GLOBAL LEADERS also enrolled patients 
with acute MI, and a generally lower cardiovascular risk, 
as demonstrated by the overall all-cause mortality, the pre-
sented findings cannot be directly compared to prior stud-
ies evaluating ticagrelor in relation to baseline renal func-
tion. A patient cohort with a risk profile which is higher 
than GLOBAL LEADERS, and comparable to PEGASUS-
TIMI 54, has been recently evaluated in the TWILIGHT 
trial, in which presence of chronic kidney disease was one 
of the enrichment factors according to the trial protocol 
[35]. In TWILIGHT, comparing ticagrelor monotherapy 
following 3-month event-free period of DAPT after PCI 
with DAPT strategy, a significant reduction of the compos-
ite primary endpoint of bleeding BARC 2, 3 or 5 type (HR 
0.56, 95% CI 0.45–0.68, pfor superiority < 0.001) has been 
demonstrated in the experimental group versus the refer-
ence group 15 months after PCI (12 months after randomi-
zation) [36]. The trial also showed non-inferiority of the 
experimental treatment with regard to the composite sec-
ondary endpoint of all-cause death, non-fatal MI, or stroke 
(HR 0.99, 95% CI 0.78–1.25, pfor non-inferiority < 0.001), with 
the caveat of a higher than anticipated drop-out in the first 
3 months after the index procedure, leading to a lower rate 
of this endpoint and potential bias of the results towards 
null hypothesis [36, 37].
Limitations
This study has several limitations. Given that two anti-
platelet strategies did not differ significantly with respect 
to the rates of the primary endpoint in the overall trial 
[11], all presented findings have to be considered explor-
atory and hypothesis-generating. The randomization in 
GLOBAL LEADERS study was not stratified for renal 
function; thus some imbalance between the randomized 
groups may exist among patients with IRF. Importantly, 
this was a prespecified subgroup analysis based on pre-
specified cut-off points of renal function at admission. 
Creatinine data were not available in 85 patients (0.5%); 
however, this rate of missing creatinine data is signifi-
cantly lower, compared to prior trials on antiplatelet agents 
in context of renal dysfunction [9].
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GLOBAL LEADERS was an open label trial; however, 
to minimize bias, the primary endpoint included solid 
components of all-cause mortality—not requiring adju-
dication, and a core lab adjudicated new-Q wave MI. No 
central adjudication of investigator-reported secondary 
clinical outcomes was performed. Bias and misclassifica-
tion can, therefore, not be excluded. This limitation should 
be considered in particular when interpreting bleeding 
event rates. However, the trial was monitored for event 
definition consistency and event under-reporting, with as 
many as seven on-site monitoring visits done at individual 
sites and one-fifth of events verified based on the source 
documentation [11, 38]. Use of site-reported endpoints is 
a valid methodology in clinical research, especially involv-
ing large cohorts and well-defined and restricted catego-
ries within a classification (e.g. BARC-defined bleeding 
type 3–5 as compared with type 1 and 2) are expected 
to provide higher concordance among sites than a central 
clinical event adjudication committee, as well as higher 
reproducibility.
Conclusions
IRF is associated with worse short- and long-term clinical 
outcomes after PCI. There were no differential treatment 
effects found with regard to all-cause death or new Q-wave 
MI after PCI in patients with IRF treated with ticagrelor 
monotherapy after 1-month dual therapy with aspirin. In 
ACS patients with IRF, the experimental strategy may be 
associated with less ischemic events and similar bleeding 
rates, compared to standard DAPT after PCI.
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